First Tracks Biotherapeutics, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b trial in celiac disease. In a 32-patient study (17 ANB033, 15 placebo), ANB033 achieved statistically significant protection against gluten-induced intestinal damage (Vh:Cd ratio placebo-adjusted delta +0.49, p=0.009) and symptoms (prevented symptom increase vs. marked increase in placebo), with no serious adverse events. The company plans to initiate late-stage development in 2027 and expects Cohort 2 data in Q1 2027.
Why this rating
Phase 1b efficacy data on lead candidate significantly de-risks regulatory pathway and program value. Early-stage biotech; positive clinical proof-of-concept for single indication materially strengthens pipeline prospects and near-term financing/partnership optionality.
Tradability signal
NO TRADE
No trade: positive news with only -2.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.51% over 4 hrs, n=187). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $34.05 ▲ 0.59% | at our read · unknown $33.85 | +10 min · unknown $32.95 ▼ 2.66% | +30 min · unknown $32.47 ▼ 4.09% | +1 hr · unknown $32.05 ▼ 5.33% | +4 hrs · unknown $31.89 ▼ 5.78% |
The stock had already moved -0.59% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.